

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

(Present Status of Competition in the Pharmaceutical Industry)

THURSDAY, JULY 10, 1975

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to notice, at 10:05 a.m., in room 318, Russell Senate Office Building; Senator James Abourezk presiding.

Present: Senator Abourezk.

Also present: Benjamin Gordon, staff economist, and Kay Klatt, research assistant.

Senator ABOUREZK. The hearings will come to order.

Part of the panel is here this morning, Dr. Sims and Dr. Chester. Is that right? Dr. Felig and Dr. Larner will be here soon.

Unfortunately, I have to run over to the Senate Democratic Caucus for a few minutes. I am going to open the hearings now, and you can begin your testimony. I shall ask Benjamin Gordon, our staff economist to receive your testimony until I come back, so that we do not interrupt the hearings. I shall be back as soon as I can.

So, if you are ready to begin your testimony, we are ready to receive it.¹

STATEMENT OF EDWARD M. CHESTER, M.D., PROFESSOR OF MEDICINE, CASE WESTERN RESERVE UNIVERSITY, AND DIRECTOR, AMBULATORY MEDICINE TEACHING CLINIC, CLEVELAND METROPOLITAN GENERAL HOSPITAL

Dr. CHESTER. Mr. Chairman, I am pleased to respond to the invitation to testify concerning the use of oral hypoglycemic agents in the treatment of diabetes mellitus.

I am a professor of medicine at Case Western Reserve University and director of the ambulatory medicine teaching clinic at Cleveland Metropolitan General Hospital. A large segment of my time is devoted to teaching 3- and 4-year medical students during their clinical clerkships.

My research efforts have been directed toward an understanding of the eye changes which are associated with diabetes mellitus. For

¹ See prepared statement, page 13643.